MalarVx, Inc.
MalarVx, Inc. is a Seattle-based biopharmaceutical company dedicated to developing effective malaria vaccines. Founded in 2012, the company aims to eradicate malaria through innovative technologies, including RNA-based vaccines and in vitro culture systems for the malaria parasite. They focus on creating safe, effective, and long-lasting vaccines to combat malaria globally, addressing the significant health burden caused by _Plasmodium_ parasites, especially in endemic regions like sub-Saharan Africa.
Industries
Nr. of Employees
small (1-50)
MalarVx, Inc.
Products
Replicon RNA-based CSP malaria vaccine candidate
A clinical-stage malaria vaccine candidate using self-amplifying replicon RNA encoding circumsporozoite protein antigens formulated with lipid nanoparticle-style delivery for induction of immune responses against Plasmodium falciparum.
In vitro-cultured sporozoite whole-organism vaccine project
Research and development project focused on producing attenuated or whole-organism malaria vaccine materials via in vitro culture of mosquito-stage parasites to reduce dependence on mosquito-derived sporozoites.
Replicon RNA-based CSP malaria vaccine candidate
A clinical-stage malaria vaccine candidate using self-amplifying replicon RNA encoding circumsporozoite protein antigens formulated with lipid nanoparticle-style delivery for induction of immune responses against Plasmodium falciparum.
In vitro-cultured sporozoite whole-organism vaccine project
Research and development project focused on producing attenuated or whole-organism malaria vaccine materials via in vitro culture of mosquito-stage parasites to reduce dependence on mosquito-derived sporozoites.
Services
Collaborative research and development partnerships
Partnered R&D collaborations with academic labs, research institutes, and industry partners for vaccine formulation, immunology analysis, and parasite culture.
Collaborative research and development partnerships
Partnered R&D collaborations with academic labs, research institutes, and industry partners for vaccine formulation, immunology analysis, and parasite culture.
Expertise Areas
- Clinical-stage vaccine development
- Malaria parasite biology and in vitro culture
- Vaccine formulation and nucleic acid delivery
- Whole-organism vaccine production
Key Technologies
- Self-amplifying replicon RNA (replicon RNA) platforms
- Lipid nanoparticle-style vaccine delivery
- In vitro sporozoite and mosquito-stage culture systems
- Whole-organism vaccine production methods